Inositol 1,4,5-trisphosphate receptor-associated 2 (IRAG2)

Inositol 1,4,5-trisphosphate receptor-associated 2 (IRAG2), also called lymphoid-restricted membrane protein (LRMP) or Jaw1, is a type II transmembrane protein predominantly localized to the cytoplasmic face of the endoplasmic reticulum and, to some extent, the outer nuclear membrane[1][2][3][5]. It is highly expressed in developing lymphoid cells, especially in B cells associated with germinal centers, and plays roles in immune cell differentiation, nuclear envelope architecture, and signal transduction[1][2][3][5]. IRAG2 interacts with inositol 1,4,5-trisphosphate receptors, enhancing release of calcium from intracellular stores, and differs from its homolog IRAG1 by promoting—rather than inhibiting—calcium release after phosphorylation by cGMP-dependent protein kinase I[2]. It also contributes to the maintenance of nuclear morphology via interactions with SUN-domain proteins and microtubules as part of the LINC complex[2][5]. Functional variants of IRAG2 have been linked to cancer behavior and autoimmune susceptibility, but no drugs are currently known to target this protein directly[5][1].

Other names

Lymphoid-restricted membrane proteinLRMPJaw1Protein Jaw1Processed inositol 1,4,5-triphosphate receptor-associated 2

Hypothetical: Modulation of ER calcium release via IP₃ receptor regulation (not known to have any approved or investigational drugs as direct modulators)